Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Xegen logo — Biostatistics & Bioinformatics company specialized in Next G...

Xegen

Biostatistics & Bioinformatics company specialized in Next Generation Sequecing data analysis

Founded 2012 France France 3 employees Seed Biotechnology, Clean Energy

General Information

Company Name Xegen
Founded Year 2012
Location France France
Employees 3
Industries Biotechnology, Clean Energy
Funding Stage Seed
Business Model B2B, SaaS, API
Revenue Model Service Fee, Subscription, Licensing
Social

BounceWatch is an independent company data service, not affiliated with Xegen. To contact Xegen, visit xegen.fr.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Xegen compare?

A PDF of Xegen and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Xegen soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Xegen

Xegen is a specialized bioinformatics company established in 2012 with a focus on Next Generation Sequencing (NGS) data analysis. Based in France, Xegen addresses complex NGS data processing challenges by providing specific, automated, and high-value bioinformatics analyses to its customers and partners.

The company is particularly notable for developing Polypheme, a comprehensive bioinformatics suite specialized in the analysis of complex genes and polymorphisms detection. Polypheme supports both classic (like HLA-A, -B, -C, DRB1, DQB1) and non-classic genes (such as HLA-E, -F, -G, -H), and aids in the discovery of new alleles, representative of Xegen's cutting-edge capabilities in leveraging bioinformatics for genomic exploration.

The company's initial investment was a spinout on 01 July 2012, backed by notable entities like SATT Sud-Est, CNRS Innovation, and the French National Centre for Scientific Research - CNRS. Positioned at the intersection of Biotechnology and Clean Energy, Xegen presents significant growth potential for investors interested in advanced genomic solutions and sustainable innovation.

Business keywords: Bioinformatics, Next Generation Sequencing, NGS Data Analysis, Polymorphisms Detection, Allelic Typing, HLA Typing, Complex Gene Analysis, Automated Bioinformatics, HLA-A, HLA-B, HLA-C, DRB1, DQB1, New Alleles Discovery, Personalized Medicine

Services & Products

Bioinformatics Tools
NGS/RNA Seq Analysis
Custom Data Analysis Pipelines
Metagenomics Analysis

Target Customers

Research Institutions Biotech Companies Pharmaceutical Companies Healthcare Organizations

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Spinout Undisclosed 3
SATT Sud-Est CNRS Innovation
SATT Sud-Est, CNRS Innovation +1
01 Jul 2012

Xegen Alternatives & Competitors

View All Alternatives
Xegen vs
Phase Genomics
Phase Genomics United States

Blueprints for Biology™: Hi-C Genomics, Metagenomics, and Epigenomics

13 employees
Biotechnology, Clean Energy
Xegen vs
MindWalk Corp. (formerly BioStrand)
MindWalk Corp. (formerly BioStrand) United States

This page is no longer actively updated. For future updates follow: MindWalk Holdings Corp.

Grant
4 employees
Biotechnology, Life Sciences
Xegen vs
Personal Genome Diagnostics
Personal Genome Diagnostics

Leading the way in patient-specific cancer genome analysis with groundbreaking technologies for non-...

Series C
0-1 employees
Analytics, Biotechnology
Also compare with: Xegen vs DNAnexus DNAnexus View all alternatives

FAQ About Xegen

Biostatistics & Bioinformatics company specialized in Next Generation Sequecing data analysis
Xegen was founded in 2012.
Xegen is headquartered in France.
Xegen operates in Biotechnology and Clean Energy. Its work centres on Bioinformatics, Next Generation Sequencing, NGS Data Analysis and Polymorphisms Detection. Its customers include Research Institutions, Biotech Companies and Pharmaceutical Companies.
Xegen has a B2B, SaaS and API business model. Its revenue comes from Service Fee, Subscription and Licensing.
Xegen has approximately 3 employees.
Xegen has completed 1 funding round. The latest funding stage is Seed.
Xegen offers: Bioinformatics Tools, NGS/RNA Seq Analysis, Custom Data Analysis Pipelines, Metagenomics Analysis.
Top alternatives and competitors to Xegen include Phase Genomics, MindWalk Corp. (formerly BioStrand), Personal Genome Diagnostics, Biotia, Novogene Europe. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Xegen and Phase Genomics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Xegen, https://bouncewatch.com/company/xegen, updated 23 November 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout